State Street’s NewAmsterdam Pharma NAMS Stock Holding History

State Street’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.9M	Buy	115,215 +52,125	+83%	+$1.72M	﹤0.01%	3117
2026 Q1	$2.02M	Sell	63,090 -5,433	-8%	-$177K	﹤0.01%	3300
2025 Q4	$2.4M	Buy	68,523 +4,713	+7%	+$172K	﹤0.01%	3286
2025 Q3	$1.81M	Sell	63,810 -17,494	-22%	-$419K	﹤0.01%	3365
2025 Q2	$1.47M	Buy	81,304 +14,606	+22%	+$266K	﹤0.01%	3401
2025 Q1	$1.37M	Buy	66,698 +6,440	+11%	+$143K	﹤0.01%	3364
2024 Q4	$1.55M	Buy	60,258 +22,343	+59%	+$475K	﹤0.01%	3391
2024 Q3	$629K	Buy	37,915 +23,805	+169%	+$412K	﹤0.01%	3554
2024 Q2	$271K	Buy	+14,110	New	+$283K	﹤0.01%	3733

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

State Street's NAMS Position: Q2 2026 in Review

State Street increased its NewAmsterdam Pharma (NAMS) stake by 83% in Q2 2026, buying an estimated $1.72M and bringing the position to 115,215 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3117.

State Street first reported a position in NAMS in Q2 2024 and has held it in 9 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

State Street held 115,215 shares of NewAmsterdam Pharma worth $3.9M as of Q2 2026.
State Street bought 52,125 NewAmsterdam Pharma shares in Q2 2026, an estimated $1.72M.
NewAmsterdam Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3117 holding.
State Street first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 9 quarters since.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.